Cell and Gene Therapy Trends for 2026: Navigating the Evolution of Advanced Therapeutics
By the end of 2026, the way we manufacture cell and gene therapies will look fundamentally different than it does today. Not because of scientific breakthroughs alone, but because operational realities are forcing a transformation that’s long overdue. The cell and gene therapy (CGT) landscape stands at a pivotal moment. With over 3,700 therapies in clinical and preclinical development and 76 products already launched globally, 2026 promises to be a defining year where innovation meets operational reality. For patient-centric organizations, CMOs, and CDMOs, understanding these emerging trends is not just about staying current, it’s about positioning your operations for sustainable …
Supply Chain Integration with PragLife: Orchestrating Seamless Connectivity Across the Cell & Gene Therapy Ecosystem
In cell and gene therapy manufacturing, the difference between a life-saving treatment reaching a patient on time and a critical delay often comes down to one factor: supply chain integration. The complexity is staggering. A single CAR-T therapy journey involves coordinating patient enrollment, apheresis scheduling, cryopreservation, transportation across multiple time zones, GMP manufacturing, quality control, final product delivery, and patient infusion, all while maintaining perfect Chain of Identity (COI) and Chain of Custody (COC) at every touchpoint. Manual coordination across these stakeholders is not just inefficient. It’s a patient safety risk. The Integration Imperative in Personalized Therapies Cell and gene …
Why Cell Therapy Supply Chains Need Cellular Orchestration Platforms
The cell and gene therapy (CGT) landscape has evolved dramatically over the past decade. With over 3,000 clinical trials worldwide and commercial therapies reaching patients at unprecedented speed, the industry faces a critical challenge orchestrating increasingly complex supply chains that span continents and involve multiple stakeholders. Unlike traditional pharmaceuticals manufactured in standardized batches, cell therapies follow a personalized model where each treatment is unique to one patient. This fundamental difference creates cellular orchestration challenges that traditional supply chain management approaches simply cannot address. The Complexity Challenge in Cell Therapy Supply Chains Cell therapy supply chains operate fundamentally differently from conventional …
